Vaccinex, Inc.VCNX
...Loading VCNX Peers...
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
37 Employees
CEO : Dr. Maurice Zauderer Ph.D.
Address : 1895 Mount Hope Avenue, Rochester,NY, US, - 14620,
| Key Excutives | Designation |
|---|---|
| Dr. John E. Leonard Ph.D. | Senior Vice President of Development |
| Ms. Jill Sanchez CPA | Chief Financial Officer |
| Dr. Ernest S. Smith Ph.D. | Senior Vice President of Research & Chief Scientific Officer |
| Dr. Maurice Zauderer Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Elizabeth E. Evans Ph.D. | Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine |